Cancer can cause kidney failure through a surprisingly wide range of pathways. A tumor can physically block urine flow, invade kidney tissue, flood the bloodstream with toxic metabolic byproducts, or trigger immune reactions that damage the kidneys from within. On top of that, many cancer treatments themselves are hard on the kidneys, adding a second layer of risk. Understanding how these mechanisms overlap matters because catching kidney problems early in cancer patients can change treatment options and outcomes.
Tumors That Physically Block the Urinary Tract
One of the most straightforward ways cancer causes kidney failure is by obstruction. Tumors in the pelvis, including cancers of the bladder, cervix, prostate, and rectum, can press on or grow into the ureters, the narrow tubes that carry urine from the kidneys to the bladder. When one or both ureters are squeezed shut, urine backs up into the kidneys, pressure builds, and kidney function drops rapidly. If both sides are blocked, this becomes a medical emergency. Left untreated, this kind of obstruction quickly becomes fatal.1PubMed Central. The role of percutaneous nephrostomy in malignant ureteric obstruction
The obstruction does not have to come from pelvic cancers alone. Rarer tumors in children, such as rhabdomyosarcoma of the pelvis, can block both ureters simultaneously and present as sudden kidney injury requiring emergency dialysis.2Child Kidney Disease. Bilateral Ureteral Obstruction Related to Pelvic Rhabdomyosarcoma Presenting with Acute Kidney Injury: A Case Report When this happens, doctors typically drain the backed-up urine through a tube inserted through the skin into the kidney (a nephrostomy) or place a stent inside the ureter. In many cases, once the blockage is relieved and cancer treatment begins, kidney function recovers substantially.3PubMed Central. Effect of emergent nephrostomy on long-term total and split renal function in patients with upper urinary tract obstruction due to pelvic malignant tumors
Cancers That Infiltrate the Kidneys Directly
Blood cancers, particularly lymphoma, can invade kidney tissue in a more insidious way. Autopsy studies have found signs of lymphoma cells infiltrating the kidney in about a third of lymphoma patients, yet only a fraction of those people were ever diagnosed with it during their lifetime. That is because the infiltration often produces no symptoms: no flank pain, no swelling, no obvious changes in urine. Kidney failure from this kind of invasion occurs in a small percentage of affected patients, but when it does, the mechanism is thought to involve pressure from the invading cells compressing the kidney’s tiny tubules and reducing blood flow. A strong clue that this is the right explanation: once chemotherapy shrinks the lymphoma, kidney size decreases and function often bounces back quickly.4PubMed Central. The Spectrum of Kidney Involvement in Lymphoma: a Case Report and Review of the Literature
Chronic lymphocytic leukemia and similar blood cancers can also damage the kidneys in more complex ways. Beyond direct infiltration, they can trigger glomerular diseases (damage to the kidney’s filtering units) and even cause deposits of abnormal proteins within the kidneys. In a multicenter study spanning 25 years, kidney biopsies in these patients showed a range of problems, from cancer-cell invasion to several types of glomerulonephritis. The encouraging finding was that after treating the underlying blood cancer, kidney function improved in the majority of patients and nephrotic syndrome went into remission in most who had it.5PLoS ONE. The Spectrum of Kidney Pathology in B-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: A 25-Year Multicenter Experience
Abnormal Proteins From Blood Cancers
Multiple myeloma, a cancer of plasma cells, deserves its own mention because it damages kidneys through a specific mechanism. Myeloma cells produce large quantities of abnormal protein fragments called free light chains. These fragments are small enough to be filtered by the kidneys, where they interact with a protein naturally present in the tubules called Tamm-Horsfall protein. The two clump together, forming casts that physically plug up the kidney’s drainage system from the inside. This condition, called cast nephropathy, is one of the defining complications of myeloma and can lead to severe kidney failure if not treated quickly.6PubMed Central. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy
Metabolic Emergencies That Wreck the Kidneys
Cancer can also cause kidney failure indirectly, through metabolic chaos. Two situations stand out: tumor lysis syndrome and malignancy-associated hypercalcemia.
Tumor lysis syndrome happens when cancer cells die rapidly, usually right after chemotherapy begins for fast-growing cancers like certain leukemias and lymphomas. Dying cells spill their internal contents into the bloodstream all at once, including uric acid, potassium, and phosphorus. The flood of uric acid and phosphorus can crystallize inside the kidney tubules, blocking them and causing acute kidney injury. Without prompt treatment, the cascade of metabolic problems can be life-threatening.7PubMed. Management of acute kidney injury in tumor lysis syndrome: a narrative review
Hypercalcemia, or dangerously high calcium levels, is another common metabolic complication in cancer patients. It occurs most often with cancers of the lung, breast, and certain blood cancers. The excess calcium causes the small arteries feeding the kidneys to constrict, reducing blood flow and triggering acute injury. It also disrupts the kidneys’ ability to concentrate urine by interfering with water-channel proteins in the collecting tubules, leading to excessive urination, dehydration, and a vicious cycle that worsens kidney function further.8Kidney Medicine. Management of Malignancy-Associated Hypercalcemia: A Narrative Review
When Cancer Treatment Itself Damages the Kidneys
Here is where the picture gets especially complicated: the therapies used to fight cancer are, in many cases, toxic to the kidneys themselves. The list of offenders is long, and it keeps growing as new treatment classes enter the clinic.
Cisplatin, one of the most widely used chemotherapy drugs, is among the worst kidney offenders. The drug is a small, uncharged molecule that passes freely through the kidney’s filtration system and accumulates in the cells lining the kidney tubules, particularly in the inner portion of the kidney. Once concentrated there, it triggers cell death through a combination of DNA damage, oxidative stress, and inflammation.9PubMed Central. Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies This is not a rare side effect. Cisplatin-induced kidney injury is common enough that researchers have spent decades searching for urinary biomarkers that could predict it early, though these have yet to make it into routine practice due to a lack of large validation studies.10PubMed Central. Preventive strategies for acute kidney injury in cancer patients
Immune checkpoint inhibitors, the drugs that have revolutionized treatment of melanoma, lung cancer, and many other cancers, carry their own kidney risks. By unleashing the immune system against cancer cells, these drugs can also trigger friendly fire against healthy tissue. The most common kidney side effect is acute interstitial nephritis, essentially inflammation of the tissue surrounding the tubules. In one large study of checkpoint-inhibitor-related kidney injury, this pattern was found in about 83% of biopsied patients.11Journal for ImmunoTherapy of Cancer. Acute kidney injury in patients treated with immune checkpoint inhibitors The good news is that many of these cases respond to stopping the drug and giving steroids. The bad news is that it can be tricky to distinguish from other causes of kidney injury in a cancer patient who may be on multiple nephrotoxic drugs at once.
Drugs that block the VEGF signaling pathway, used against cancers that rely on growing new blood vessels, can cause a specific kind of kidney damage called thrombotic microangiopathy, where tiny clots form in the kidney’s smallest blood vessels.12PubMed Central. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities And for patients who undergo bone marrow transplantation, radiation used during conditioning regimens adds yet another source of kidney injury. Higher radiation doses and the development of graft-versus-host disease after transplant are both independently linked to worse kidney outcomes.13PubMed. Renal toxicity after allogeneic bone marrow transplantation: the combined effects of total-body irradiation and graft-versus-host disease
Losing a Kidney to Surgery
When the cancer is in the kidney itself, treatment often means removing part or all of it. This creates a paradox: curing the cancer can set the stage for chronic kidney disease down the road. A retrospective study comparing partial and radical nephrectomy found a stark difference. Three years after surgery, 80% of patients who kept part of their kidney still had normal function, compared to only about 35% of those who lost the entire kidney.14PubMed Central. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study After adjusting for other health factors, radical nephrectomy carried roughly four times the risk of developing reduced kidney function compared to a partial procedure.15PubMed Central. The incidence and risk factors of chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma This is a major reason surgeons now favor kidney-sparing surgery whenever the tumor’s location and size allow it.
Paraneoplastic Kidney Disease
Sometimes the kidneys are damaged not by the tumor itself but by the body’s misguided immune response to it. In paraneoplastic syndromes, the immune system produces antibodies or inflammatory signals in reaction to a cancer, and those signals happen to attack normal kidney tissue. One well-described pattern is membranous nephropathy, a condition where antibodies deposit along the kidney’s filtering membranes, causing protein to leak into the urine and the kidneys to gradually fail. This has been linked to solid tumors of the lung, prostate, and gastrointestinal tract. In a reported case involving triple-negative breast cancer, the patient’s membranous nephropathy and autoantibodies resolved completely after curative cancer treatment, confirming that the cancer had been driving the kidney disease all along.16PubMed Central. Complete Resolution of Paraneoplastic Membranous Nephropathy Following Curative Therapy of Triple-Negative Breast Cancer
Paraneoplastic kidney disease is worth knowing about because it can be the first sign that a cancer exists. A person who shows up with unexplained protein in their urine and kidney biopsy findings consistent with membranous nephropathy may need cancer screening, particularly if they are in an older age group or have other risk factors.
Sepsis and the Critically Ill Cancer Patient
Cancer patients are at heightened risk of infections, partly because the disease and its treatments suppress the immune system. When infections progress to sepsis, the resulting drop in blood pressure and disruption of blood flow to the kidneys can cause acute kidney injury. Research on cancer patients admitted to intensive care with sepsis has shown that septic shock triggers not just low blood pressure but dysfunction of the kidney’s own blood-vessel network, causing a severe drop in the kidney’s filtration rate.17PubMed Central. Incidence, risk factors and clinical outcomes of septic acute renal injury in cancer patients with sepsis admitted to the ICU: A retrospective study This layered vulnerability, where cancer and its treatment weaken the immune system, infections take hold more easily, and the resulting sepsis hammers the kidneys, is one of the most common scenarios oncologists face in hospital settings.
Why Measuring Kidney Function in Cancer Patients Is Tricky
A hidden complication in all of this is that the standard way doctors estimate kidney function can be unreliable in people with cancer. The most common blood test for kidney function relies on creatinine, a waste product generated by muscles. But many cancer patients lose significant muscle mass due to the disease itself or treatment side effects, a condition called sarcopenia. With less muscle producing creatinine, blood levels stay deceptively low even when the kidneys are struggling. The result is that standard formulas overestimate kidney function, potentially leading doctors to prescribe full doses of drugs the kidneys cannot safely handle.18PubMed Central. Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer
This is not a minor technical issue. Overestimating kidney function in a cancer patient can lead to overdosing of toxic chemotherapy, while underestimating it can lead to underdosing and treatment failure.19PubMed Central. Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing Factors beyond sarcopenia also skew the numbers: fluid shifts from aggressive hydration or edema, and certain drugs that interfere with creatinine secretion in the kidneys, can all distort the picture.20PubMed Central. GFR Evaluation Among Patients with Cancer: Insights and Clinical Implications Some researchers advocate using cystatin C, an alternative blood marker that is less affected by muscle mass, or cross-referencing body-composition data from CT scans that cancer patients are already getting for other reasons. These approaches have shown promise but are not yet standard practice everywhere.
The Two-Way Street Between Cancer and Kidney Disease
The relationship between cancer and kidney disease runs in both directions. Not only can cancer cause kidney failure, but chronic kidney disease may itself raise the risk of developing certain cancers. The two conditions share several root causes, including smoking, obesity, and metabolic disorders like diabetes. Chronic low-grade inflammation, immune dysfunction, and impaired clearance of toxins in patients with reduced kidney function may all contribute to a higher cancer risk over time.21Nephrology Dialysis Transplantation. The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes This bidirectional link has given rise to a growing field sometimes called onco-nephrology, which focuses on managing patients caught at the intersection of both diseases.22PubMed Central. Chronic kidney disease and cancer: a troubling connection
Dialysis Decisions in Older Cancer Patients
When kidney failure does develop in someone with advanced cancer, particularly an older patient, the decision about whether to start dialysis is rarely straightforward. Dialysis is physically demanding, requires frequent hospital visits, and carries its own complications. For a patient whose cancer prognosis is already poor, dialysis may extend life without meaningfully improving its quality. Medical guidelines recognize that choosing not to start dialysis, or stopping it after it has been started, is a legitimate treatment option in older cancer patients when the overall prognosis is unfavorable. The ethical obligation of the medical team in these situations is to clearly explain both the risks and benefits of dialysis and the alternative of conservative management with palliative care, allowing the patient and their family to make an informed choice.23The Lancet. Management of older patients with cancer and end-stage kidney disease
These conversations are becoming more common as both cancer and chronic kidney disease grow more prevalent in aging populations. The emerging consensus in onco-nephrology is that kidney function monitoring should be woven into cancer care from the very beginning, not treated as an afterthought when creatinine levels spike. Early detection of kidney damage opens the door to dose adjustments, drug switches, and supportive measures that can preserve enough kidney function to keep treatment options on the table.